This Government Contract opportunity from Department Of Defense was posted on September 5, 2018. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Advanced Technology Innovation (ATI) Broad Agency Announcement

Awarded

HQ0147-15-ATI-BAAFederal

Submission Closed08/31/2018, 12:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Quantitative Analysis of Longitudinal MR Images

Solicitation # 75N98027R00005

Solicitation 75N98027R00005 is a Sources Sought notice issued by the National Institute on Aging (NIA) to identify qualified companies capable of performing quantitative analysis of longitudinal Magnetic Resonance (MR) images. The project supports the Baltimore Longitudinal Study of Aging (BLSA) by processing 300 newly acquired MR datasets to characterize brain aging trajectories and identify predictors of cognitive decline and Alzheimer’s disease. The selected contractor will provide specialized, non-commercial services to deliver global and regional tissue volumes, lesion quantification, and machine learning-derived scores, such as SPARE-AD, while ensuring longitudinal consistency with data acquired since 1994. The anticipated contract will be a firm fixed price award with a period of performance of one year. Key deliverables include quantitative volumetric results, intermediate processing files, and registration maps for PET overlay, submitted every six months, concluding with a final report. Technical requirements emphasize the use of established image analysis tools and adherence to FISMA/FedRAMP-aligned data security controls to protect participant confidentiality. Interested respondents must submit a capability statement by November 9, 2026, to Contract Specialist Sneha Singh. The submission must be limited to ten pages and include the company's Unique Entity ID, NAICS code 541714, professional qualifications of personnel, and any applicable GSA schedules or government-wide acquisition contracts. Small businesses are encouraged to respond to this market research effort to help the government determine the appropriate acquisition method.

National Institutes Of Health Olao

POSTED

DEADLINE

Q--AMPLICON SEQUENCING SERVICES

Solicitation # 140G0226Q0047

The Department of the Interior, through the USGS OAG Denver Acquisition Branch, is soliciting quotations for a Blanket Purchase Agreement (BPA) to provide next-generation amplicon sequencing services for the Michigan Bacteriological Research Laboratory. The agreement has a not-to-exceed value of $250,000 over a five-year period of performance from September 17, 2026, to September 16, 2031. The scope of work includes non-personal services such as library preparation for 16S V4 amplicon sequencing, library pooling, and sequencing using Illumina MiSeq or AVITI platforms to support research on bacterial pathogens, antibiotic resistance, and microbial ecology. Key deliverables include demultiplexed raw data and reporting metrics, with a required delivery turnaround of 60 business days from sample receipt. Award decisions will be based on technical and priced factors, with non-priced factors carrying significantly more weight. Technical evaluations will focus on the contractor's on-site equipment, personnel experience, quality control procedures, business establishment, and a capabilities narrative. Offerors must also provide two customer references from the last five years. The contract is subject to various federal regulations, including specific security prohibitions regarding certain telecommunications equipment and the requirement for electronic invoicing through the Invoice Processing Platform System. Quotations are due by November 5, 2026, and must be submitted via email to the primary point of contact.

Ofc Of Acquisition Grants-Denver

POSTED

DEADLINE

ARPA-H Emerging Health Innovators (EHI) Initiative

Solicitation # ARPA-H-SOL-26-150

The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, seeks to identify and engage early-career investigators to develop cutting-edge biomedical, health, and community-engaged research. This opportunity is open to researchers from academic, nonprofit, and industry organizations, provided the Principal Investigator is within eight years of completing their first terminal degree. The initiative covers 16 specific topic areas, including AI in life sciences, brain stimulation, and human tissue platforms. Awards are issued as Other Transaction (OT) agreements, which are not subject to the Federal Acquisition Regulation (FAR). The selection process is a two-step submission involving an initial anonymized Solution Summary and a subsequent Full Proposal for selected candidates. Successful awards have a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a 24-month base period capped at 700,000 dollars and an optional 12-month Director's Award period capped at 350,000 dollars. Payments are structured as fixed payments triggered by the completion of 12 discrete, measurable milestones. Full proposals are evaluated based on technical merit, innovativeness, feasibility, alignment with the ARPA-H mission to accelerate health outcomes, and price reasonableness. Administrative requirements include mandatory registration in SAM.gov and the use of the ARPA-H Solutions site for all submissions. Proposers must adhere to strict formatting templates for technical and management proposals, milestone schedules, and national policy requirements, including disclosures regarding organizational conflicts of interest and research security. Performance is monitored through a formal inspection and acceptance process where the government reviews deliverables within 14 calendar days. The tentative award start date is June 30, 2027, with full proposals due by February 10, 2027.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.

POSTED

DEADLINE

AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.

POSTED

DEADLINE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)

Solicitation # W911SR-26-R-HEAL

The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.

POSTED

DEADLINE

AJ12--Development/Production - Kidney GEC-Specific AAV Vector

Solicitation # 36C24E27Q0009

The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.

POSTED

DEADLINE

MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.

National Institutes Of Health

POSTED

DEADLINE

Discovery Gateway to Reproductive Health InnovationThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to establish the Discovery Gateway to Reproductive Health Innovation. This initiative aims to create a comprehensive, open-access web-based visualization platform and knowledgebase to advance research on male and female reproductive health issues, including infertility, uterine fibroids, endometriosis, preeclampsia, and preterm birth. By integrating multi-omic, pharmacogenomic, and clinical data, the Gateway seeks to fill critical knowledge gaps and provide the biomedical community with shared infrastructure to identify biomarkers, drug targets, and disease mechanisms. The primary objective of this project is to catalyze the discovery of new treatments and cures while fostering public-private partnerships and the development of commercial products. This effort aligns with recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. The opportunity is currently listed as a forecast, with administrative oversight provided by the Obstetric and Pediatric Pharmacology and Therapeutics Branch.

National Institutes Of Health

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking applications under solicitation RFA-AI-28-005 to continue the Immune Tolerance Network. The primary goal of this initiative is the development of tolerogenic therapies targeting autoimmune diseases, allergic diseases and asthma, and immune-mediated consequences of transplantation. The network is tasked with the core functions of designing and conducting clinical trials, performing integrated mechanistic studies, and sharing the resulting data. This federal solicitation was posted on October 20, 2026, and requires responses by January 30, 2027. As a UM1 clinical trial requirement, the project emphasizes a collaborative approach to advancing medical treatments for immune-mediated disorders through rigorous clinical research and analysis.

National Institute Of Allergy And Infectious Diseases

POSTED

5 days ago

DEADLINE

in 3 months

AI Contract Overview

General Atomics Electromagnetic Systems, based in San Diego, California, was awarded a cost-plus-fixed-fee contract modification, P00009, by the Missile Defense Agency in Albuquerque, New Mexico. This modification increases the total value of contract HQ0277-18-C-0002 from 10,252,260 dollars to 33,957,508 dollars, adding 23,432,248 dollars to the agreement. The funding is designated for the completion of a tailored Critical Design Review to support risk reduction for the Low Power Laser Demonstrator following the Preliminary Design Review. The project is funded through Fiscal 2018 Research, Development, Test and Engineering funds, with 12,000,000 dollars obligated at the time of the award. This modification extends the original period of performance, which began on June 28, 2018, by an additional 11 months, establishing a new completion date of September 6, 2019. The effort falls under the Advanced Technology Innovation Broad Agency Announcement and is categorized under NAICS code 541714.

General Info

Agency

Department Of Defense → Missile Defense Agency

Contract Value

$933,141

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

NM, USA

Set-Aside

NONE

Awardee

Northrop Grumman Systems Corporation - Mission Systems Sector 1580-A West Nursery Rd. Linchicum MD 21090 USA

Award Issued Date

03/22/2018, 12:00:00 AM UTC

Documents

General Atomics LPLD Award Announcement (08.31.2018)

award

Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

11 updates

PhaseAwarded

PostedFeb 26

Presolicitation

Notice updatedMay 1

The notice description changed.

Notice updatedAug 26

The point of contact changed.

Notice updatedSep 14

Notice details unchanged. Attachments may have changed.

Notice updatedSep 27

The notice description changed. The point of contact changed.

Notice updatedSep 27

The notice description changed.

Notice updatedSep 27

The notice description changed.

Notice updatedOct 31

The notice description changed.

Notice updatedNov 16

Notice details unchanged. Attachments may have changed.

Notice updatedNov 16

The notice description changed.

Notice updatedFeb 28

The notice description changed.

Notice updatedMar 2

Notice details unchanged. Attachments may have changed.

Type ChangedMar 2

Presolicitation → Solicitation

AwardedMar 22

Contract was awarded

Submission Closed

08/31/2018, 12:00:00 AM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → Missile Defense Agency

Contacts1 person available

OfficeKIRTLAND AFB, NM, 871175526, USA

Organization / AgencyDepartment Of Defense → Missile Defense Agency

Office AddressKIRTLAND AFB, NM, 871175526, USA

Contacts

Anne PeelContracting Officer

contact@example.gov

+1 (555) 000-0000

Full Description

General Atomics (GA) Electromagnetic Systems, San Diego, California, is being awarded a $23,432,248 cost-plus-fixed-fee contract modification (P00009) to a previously awarded HQ0277-18-C-0002 contract. The value of this contract is increased from $10,252,260 to $33,957,508. Under this modification, the contractor will complete their tailored Critical Design Review in support of the Low Power Laser Demonstrator (LPLD) post-Preliminary Design Review (PDR) risk reduction. The work will be performed in San Diego, California. The current period of performance is June 28, 2018 to October 3, 2018. This effort will extend the period of performance an additional 11 months to September 6, 2019. Fiscal 2018 Research, Development, Test and Engineering funds in the amount of $12,000,000 are being obligated at the time of award. The Missile Defense Agency, Albuquerque, New Mexico, is the contracting activity. Contracting Office Point of Contact: Anne C. Peel, 505-846-3117 Report Control Symbol: DD-LA-AR-1279 Award from HQ0147-15-ATI-BAA

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS